{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:36:26Z","timestamp":1781278586646,"version":"3.54.1"},"reference-count":72,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The most common type of alopecia in women is female androgenetic alopecia (FAGA), characterized by progressive hair loss in a patterned distribution. Many oral therapies, including spironolactone (an aldosterone antagonist), androgen receptor blockers (e.g., flutamide\/bicalutamide), 5-alpha-reductase inhibitors (e.g., finasteride\/dutasteride), and oral contraceptives, target the mechanism of androgen conversion and binding to its respective receptor and therefore could be administered for the treatment of FAGA. Despite significant advances in the oral treatment of FAGA, its management in patients with a history of gynecological malignancies, the most common cancers in women worldwide, may still be a concern. In this review, we focus on the safety of antiandrogens for the treatment of FAGA patients. For this purpose, a targeted literature review was conducted on PubMed, utilizing the relevant search terms. To sum up, spironolactone seems to be safe for the systemic treatment of FAGA, even in high-risk populations. However, a general uncertainty remains regarding the safety of other medications in patients with a history of gynecologic malignancies, and further studies are needed to evaluate their long-term safety in patients with FAGA and risk factors to establish an optimal risk assessment and treatment selection protocol.<\/jats:p>","DOI":"10.3390\/jcm13113052","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T03:49:03Z","timestamp":1716436143000},"page":"3052","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies"],"prefix":"10.3390","volume":"13","author":[{"given":"S Morteza","family":"Seyed Jafari","sequence":"first","affiliation":[{"name":"Department of Dermatology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9217-6086","authenticated-orcid":false,"given":"Kristine","family":"Heidemeyer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Hunger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre A.","family":"de Viragh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jdv.14624","article-title":"Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men\u2013short version","volume":"32","author":"Kanti","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1610-0379.2011.07802.x","article-title":"Evidence-Based (S3) Guideline for the Treatment of Androgenetic Alopecia in Women and in Men","volume":"9","author":"Blumeyer","year":"2011","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1365-2133.2001.04018.x","article-title":"Hair density, hair diameter and the prevalence of female pattern hair loss","volume":"144","author":"Birch","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-018-4996-3","article-title":"Safety of 5\u03b1-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies","volume":"174","author":"Rozner","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1001\/archderm.1975.01630230098020","article-title":"Testosterone metabolism in the skin. A review of its function in androgenetic alopecia, acne vulgaris, and idiopathic hirsutism including recent studies with antiandrogens","volume":"111","author":"Price","year":"1975","journal-title":"Arch. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/annonc\/mdt170","article-title":"Aromatase inhibitors induce \u2018male pattern hair loss\u2019 in women?","volume":"24","author":"Rossi","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_7","first-page":"13","article-title":"Female pattern hair loss may be triggered by low oestrogen to androgen ratio","volume":"42","author":"Riedel","year":"2008","journal-title":"Endocr. Regul."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1056\/NEJM199909233411307","article-title":"Treatment of hair loss","volume":"34","author":"Price","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s004030000184","article-title":"Role of androgens in female-pattern androgenetic alopecia, either alone or associated with other symptoms of hyperandrogenism","volume":"292","author":"Vexiau","year":"2000","journal-title":"Arch. Dermatol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jaad.2015.05.026","article-title":"Evidence-based approach to cutaneous hyperandrogenism in women","volume":"73","author":"Schmidt","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijwd.2017.01.001","article-title":"Hormonal therapy in female pattern hair loss","volume":"3","author":"Brough","year":"2017","journal-title":"Int. J. Womens Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1365-2133.2010.09661.x","article-title":"Female pattern hair loss in complete androgen insensitivity syndrome","volume":"162","author":"Cousen","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-2133.1999.03049.x","article-title":"Diffuse female hair loss: Are androgens necessary?","volume":"141","author":"Orme","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2133.2005.06218.x","article-title":"Treatment of female pattern hair loss with oral antiandrogens","volume":"152","author":"Sinclair","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1067\/mjd.2000.107953","article-title":"Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia","volume":"43","author":"Price","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40257-014-0077-5","article-title":"Androgenetic alopecia: An evidence-based treatment update","volume":"15","author":"Varothai","year":"2014","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/oxfordjournals.aje.a113416","article-title":"Nonestrogenic drugs and breast cancer","volume":"116","author":"Danielson","year":"1982","journal-title":"Am. J. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0277-5379(98)90011-6","article-title":"Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer","volume":"24","author":"Willemse","year":"1988","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/cncr.11663","article-title":"Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65\u201379 years","volume":"98","author":"Li","year":"2003","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pds.910","article-title":"Breast cancer incidence and use of antihypertensive medication in women","volume":"13","author":"Ronquist","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/humupd\/dmi028","article-title":"Breast cancer risk with postmenopausal hormonal treatment","volume":"11","author":"Collins","year":"2005","journal-title":"Hum. Reprod. Update"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.jhh.1002075","article-title":"Hypertension, diuretics and breast cancer risk","volume":"20","author":"Largent","year":"2006","journal-title":"J. Hum. Hypertens."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-005-9091-x","article-title":"A cohort study of antihypertensive medication use and breast cancer among Danish women","volume":"97","author":"Fryzek","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bjc.6603618","article-title":"Oral progestagens before menopause and breast cancer risk","volume":"96","author":"Fabre","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e4447","DOI":"10.1136\/bmj.e4447","article-title":"Spironolactone and risk of incident breast cancer in women older than 55 years: Retrospective, matched cohort study","volume":"345","author":"Mackenzie","year":"2012","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.canep.2013.10.004","article-title":"Spironolactone use and the risk of breast and gynecologic cancers","volume":"37","author":"Biggar","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","article-title":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer","volume":"19","author":"Gucalp","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bcp.13152","article-title":"Spironolactone use and risk of incident cancers: A retrospective, matched cohort study","volume":"83","author":"Mackenzie","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00228-019-02740-y","article-title":"Breast cancer and spironolactone: An observational postmarketing study","volume":"75","author":"Sabatier","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_30","first-page":"l1652","article-title":"Breast cancer risk in transgender people receiving hormone treatment: Nationwide cohort study in the Netherlands","volume":"365","author":"Wiepjes","year":"2019","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2020.05.081","article-title":"Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis","volume":"83","author":"Wei","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"21-e15","DOI":"10.1634\/theoncologist.2019-0564","article-title":"Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive\/Androgen Receptor-Positive Advanced Breast Cancer","volume":"25","author":"Lu","year":"2020","journal-title":"Oncologist"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamadermatol.2021.5866","article-title":"Association of spironolactone use with risk of cancer: A systematic review and meta-analysis","volume":"158","author":"Bommareddy","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamadermatol.2021.3676","article-title":"Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors","volume":"157","author":"Bhoyrul","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jdcr.2023.02.021","article-title":"Hair regrowth in endocrine therapy alopecia with dutasteride treatment in woman with estrogen positive breast cancer","volume":"35","author":"Dubin","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaad.2024.02.030","article-title":"No increased risk of breast or gynecologic malignancies in women exposed to spironolactone for dermatologic conditions: A retrospective cohort study","volume":"90","author":"Hill","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaad.2020.07.104","article-title":"Spironolactone and breast cancer: Fear not!","volume":"83","author":"Heymann","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijwd.2018.05.001","article-title":"Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review","volume":"4","author":"Fabbrocini","year":"2018","journal-title":"Int. J. Womens Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(75)92645-8","article-title":"Breast cancer associated with administration of spironolactone","volume":"305","author":"Loube","year":"1975","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(75)92814-7","article-title":"Letter: Breast cancer and spironolactone","volume":"2","author":"Jick","year":"1975","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","unstructured":"IARC (2023). List of Classifications by Cancer Sites with Sufficient or Limited Evidence in Humans, IARC. IARC Monographs."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/120347540200600604","article-title":"Long-term safety of spironolactone in acne: Results of an 8-year followup study","volume":"6","author":"Shaw","year":"2002","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.det.2018.12.002","article-title":"An Overview of Acne Therapy, Part 2: Hormonal Therapy and Isotretinoin","volume":"37","author":"Marson","year":"2019","journal-title":"Dermatol. Clin."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/jnci\/65.4.723","article-title":"Initial screening for carcinogenicity of commonly used drugs","volume":"65","author":"Friedman","year":"1980","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1038\/s41388-018-0654-9","article-title":"Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response","volume":"38","author":"Gold","year":"2019","journal-title":"Oncogene"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00403-017-1798-0","article-title":"5\u03b1-Reductase isozymes and aromatase mRNA levels in plucked hair from young women with female pattern hair loss","volume":"310","author":"Torres","year":"2018","journal-title":"Arch. Dermatol. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4103\/0974-2077.69022","article-title":"Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link?","volume":"3","author":"Shenoy","year":"2010","journal-title":"J. Cutan. Aesthet. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1158\/1055-9965.EPI-18-0904","article-title":"Finasteride Use and Risk of Male Breast Cancer: A Case-Control Study Using Individual-Level Registry Data from Denmark, Finland, and Sweden","volume":"28","author":"Green","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e624","DOI":"10.1016\/j.clbc.2019.04.006","article-title":"Analysis of Data From Breast Diseases Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia","volume":"19","author":"Fang","year":"2019","journal-title":"Clin. Breast Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/CLEP.S124674","article-title":"Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia","volume":"9","author":"Hagberg","year":"2017","journal-title":"Clin. Epidemiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s10552-014-0455-6","article-title":"Long-term use of 5\u03b1-reductase inhibitors and the risk of male breast cancer","volume":"25","author":"Duijnhoven","year":"2014","journal-title":"Cancer Causes Control"},{"key":"ref_53","first-page":"414","article-title":"Side Effects Related to 5 \u03b1-Reductase Inhibitor Treatment of Hair Loss in Women: A Review","volume":"15","author":"Seale","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"ref_54","first-page":"2250","article-title":"5alpha-reductases in human breast carcinoma: Possible modulator of in situ androgenic actions","volume":"86","author":"Suzuki","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/CEJ.0000000000000162","article-title":"Finasteride for postmenopausal breast cancer prevention","volume":"24","author":"Lehrer","year":"2015","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_56","first-page":"e13182","article-title":"Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study","volume":"33","author":"Morales","year":"2020","journal-title":"Dermatol Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.jaad.2020.09.093","article-title":"Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice","volume":"84","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2013.12.003","article-title":"Frontal fibrosing alopecia: A multicenter review of 355 patients","volume":"70","author":"Grimalt","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"150","DOI":"10.32768\/abc.201964150-155","article-title":"Miscellaneous Exogenous Hormones and Breast Diseases: A Matter of Concern for the Gynecologist","volume":"6","author":"Alipour","year":"2019","journal-title":"Arch. Breast Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/(SICI)1099-1557(199705)6:3<169::AID-PDS263>3.0.CO;2-3","article-title":"Safety of cyproterone acetate: Report of active surveillance","volume":"6","author":"Heinemann","year":"1997","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"n37","DOI":"10.1136\/bmj.n37","article-title":"Use of high dose cyproterone acetate and risk of intracranial meningioma in women: Cohort study","volume":"372","author":"Weill","year":"2021","journal-title":"BMJ"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1038\/s41598-022-05773-z","article-title":"A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas","volume":"12","author":"Lee","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1159\/000474216","article-title":"Cyproterone acetate in the treatment of advanced prostatic cancer: Retrospective analysis of liver toxicity in the long-term follow-up of 89 patients","volume":"30","author":"Hinkel","year":"1996","journal-title":"Eur. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1345\/aph.1P600","article-title":"Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss","volume":"45","author":"Paradisi","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Rahim, B., and O\u2019Regan, R. (2017). AR Signaling in Breast Cancer. Cancers, 9.","DOI":"10.3390\/cancers9030021"},{"key":"ref_66","unstructured":"Johnson, D.B., and Sonthalia, S. (2023). Flutamide, StatPearls [Internet]."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1440-0960.2010.00735.x","article-title":"Treatment of female pattern hair loss with the androgen receptor antagonist flutamide","volume":"52","author":"Yazdabadi","year":"2011","journal-title":"Australas. J. Dermatol."},{"key":"ref_68","first-page":"69","article-title":"Flutamide-induced hepatotoxicity: Ethical and scientific issues","volume":"21","author":"Giorgetti","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1111\/jocd.14773","article-title":"Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know","volume":"21","author":"Carvalho","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e19822","DOI":"10.1097\/MD.0000000000019822","article-title":"Effect of Bicalutamide on the proliferation and invasion of human triple negative breast cancer MDA-MB-231 cells","volume":"99","author":"Kong","year":"2020","journal-title":"Medicine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/j.jaad.2020.04.054","article-title":"Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss","volume":"83","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.jaad.2020.03.034","article-title":"Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients","volume":"83","author":"Ismail","year":"2020","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/11\/3052\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:46:54Z","timestamp":1760107614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/11\/3052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":72,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["jcm13113052"],"URL":"https:\/\/doi.org\/10.3390\/jcm13113052","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}